New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
JAMP-bezafibrate SR; Bezalip SR
Synonyms :
bezafibrate
Class :
Antilipemic Agent, Fibric Acid
Brand Name :
JAMP-bezafibrate SR; Bezalip SR
Synonyms :
bezafibrate
Class :
Antilipemic Agent, Fibric Acid
Dosage Forms & Strengths
Tablet
400mg
Sustained Release Tablet
400mg
400 mg orally as a sustained-release tablet once daily
Take with food
400 mg orally as a sustained-release tablet once daily
Take with food
Dosage Forms & Strengths
Tablet
400mg
Sustained Release Tablet
400mg
400 mg orally as a sustained-release tablet once daily
Take with food
400 mg orally as a sustained-release tablet once daily
Take with food
Refer to the adult dosing
may diminish the absorption when combined with fibric acid derivatives
may decrease the therapeutic effect of Fc Receptor-Binding agents
may increase the myopathic effect of HMG-CoA Reductase Inhibitors
may increase the nephrotoxic effect of cyclosporine
may diminish the absorption when combined with fibric acid derivatives
they increase the toxicity of bezafibrate
they increase the toxicity of bezafibrate
they increase the toxicity of bezafibrate
they increase the toxicity of bezafibrate
they increase the toxicity of bezafibrate
may intensify the effect of HMG-CoA Reductase Inhibitors on myopathic (rhabdomyolysis) disease
it increases the toxicity of fibric derivatives
fibric acid derivatives increase the toxicity of ezetimibe
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
When bezafibrate is used together with fluconazole, this leads to reduction in the bezafibrate metabolism
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may enhance the myopathic effect of colchicine
may increase the hypoglycemic effect of sulfonylureas
may increase the myopathic effect of Fibric Acid Derivatives
it increases the effect of myopathy on fibric acid derivatives
fibric acid derivatives increase the effect of hypoglycemia of sulfonylureas
fibric acid derivatives increase the effect of hypoglycemia of sulfonylureas
fibric acid derivatives increase the effect of hypoglycemia of sulfonylureas
fibric acid derivatives increase the effect of hypoglycemia of sulfonylureas
fibric acid derivatives increase the effect of hypoglycemia of sulfonylureas
It may enhance the risk of adverse effects when combined with Atypical Antidepressants
It may enhance the risk of adverse effects when combined with Atypical Antidepressants
It may enhance the risk of adverse effects when combined with Atypical Antidepressants
bezafibrate increases the effect of myopathy on HMG-CoA reductase inhibitors
bezafibrate increases the effect of myopathy on HMG-CoA reductase inhibitors
bezafibrate increases the effect of myopathy on HMG-CoA reductase inhibitors
bezafibrate increases the effect of myopathy on HMG-CoA reductase inhibitors
bezafibrate increases the effect of myopathy on HMG-CoA reductase inhibitors
fibric acid derivatives increase the effect of anticoagulation of vitamin K antagonists
fibric acid derivatives increase the effect of anticoagulation of vitamin K antagonists
fibric acid derivatives increase the effect of anticoagulation of vitamin K antagonists
fibric acid derivatives increase the effect of anticoagulation of vitamin K antagonists
fibric acid derivatives increase the effect of anticoagulation of vitamin K antagonists
Actions and Spectrum
Actions:
Spectrum:
>10%:
Increased creatine phosphokinase
1-10%:
Eczema (1%)
Anemia (1%)
Pruritus (3%)
Dizziness (2%)
Insomnia (1%)
Pain (1%)
<1%:
Erectile dysfunction
Urticaria
Abdominal Pain
Pancytopenia
Paresthesia
Interstitial pulmonary disease
Muscle cramps
Myalgia
Myasthenia
None
Contraindications:
Hypersensitivity
Severe liver impairment
Pregnancy
Breastfeeding
Cautions:
Medical conditions
Drug interactions
Pregnancy consideration:
The drug is contraindicated during pregnancy.
Breastfeeding warnings:
The excretion of the drug in breast milk is unknown.
Pregnancy category:
Category A: Well-controlled and satisfactory studies show no risk to the fetus in the initial or later trimester.
Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
PPAR Agonist: Bezafibrate is a peroxisome proliferate activated receptor (PPAR) agonist. It mainly activates PPAR-α receptors. Activation of PPAR- α receptors by bezafibrate can lead to upregulation of gene s which are included in the metabolism of lipid.
Reduction of Triglycerides: Bezafibrate elevates the break down triglycerides and decreases the production in the liver. This can lead to low levels of triglycerides in the bloodstream.
Pharmacodynamics:
Increase in HDL Cholesterol: Bezafibrate elevates levels of HDL which is known as good cholesterol. HDL cholesterol eliminates the extra cholesterol from the blood stream and reduces the risk of atherosclerosis. Atherosclerosis is a disease in which plaque buildup in the arteries.
Modulation of LDL Cholesterol: Bezafibrate mainly affects triglycerides and HDL cholesterol. It can reduce the LDL levels which is known as bad cholesterol. The reduction in LDL cholesterol is not used with other medications like statins.
Anti-Inflammatory Effects: Some studies have shown that bezafibrate have anti-inflammatory effects. Chronic inflammation plays an important role in the development of cardiovascular disease. The anti-inflammatory property of bezafibrate may provide benefits to the cardiovascular diseases.
Pharmacokinetics:
Absorption
It is properly absorbed in the gastrointestinal tract. The peak plasma concentrations are about 1 to 2 hours after the oral administration. Take the medication wit food so the bioavailability can increase.
Distribution
Bezafibrate is distribute in the body like in different tissues like liver. It binds to plasma proteins.
Metabolism
Bezafibrate go into the lover for metabolism. The primary metabolite formed is bezafibrate glucuronide. It is less active as a pharmacologically than the parent compound. Bezafibrate 4’ hydroxy is formed.
Elimination and Excretion
The half life of bezafibrate is about 1 to 2 hours and about 1 to 3 hours for the metabolites.
Bezafibrate is administrated orally in the from of capsules or tablets. The specific dosage and frequency of administration depends on the medical condition of patient and formulation of medication.
Generic Name: bezafibrate
Pronounced as: bee-za-fy-brate
Why do we use bezafibrate?
Bezafibrate is sued to treat lipid diseases and reduce the risk of cardiovascular diseases by reducing the high levels of cholesterol, reducing the high levels of triglyceride, managing the mixed hyperlipidemia, preventing different cardiovascular events, and treating the metabolic syndrome when it includes abnormal lipid profiles.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
